Drug Profile
IC 31 seasonal influenza vaccine - CSL/Valneva
Alternative Names: IC31® Flu vaccine - CSL/Valneva; Seasonal trivalent influenza vaccine (Agrippal® + IC31®) - CSL/ValnevaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Intercell; Novartis
- Developer CSL; Valneva
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in Austria (IM, Injection)
- 28 May 2013 Seasonal influenza prophylactic vaccine is still in phase I trials for Influenza virus infections in Austria
- 28 May 2013 Intercell has merged with Vivalis to form Valneva